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IMPROVING ACTIVITIES OF DAILY LIVING ABILITY IN WOMEN WITH FIBROMYALGIA: 
AN EXPLORATORY, QUASI-RANDOMIZED, PHASE-TWO STUDY, IMPROvE TRIAL
Cecilie VON BÜLOW, MSc, OT, PhD1,2,3, Kirstine AMRIS, MD1, Elisabeth BANDAK, MSC, PT, PhD-Student1, Bente 
DANNESKIOLD-SAMSØE MD, DMSc1 and Eva EJLERSEN WÆHRENS, MSc, OT, PhD1,2
1From the Parker Institute, Copenhagen University Hospital, Bispebjerg-Frederiksberg Hospital, 2The Research Initiative for Activity 
Studies and Occupational Therapy, General Practice, Department of Public Health, University of Southern Denmark, Odense and 
3Metropolitan University College, Copenhagen, Denmark
Objective: To explore and compare the outcomes of 
adaptation and physical activity programmes regar-
ding activities of daily living (ADL) ability following 
interdisciplinary rehabilitation in women with fibro-
myalgia. 
Methods: Participants (n = 85) were quasi-randomi-
zed to 16-week adaptation (ADAPT) or physical ac-
tivity (ACTIVE) programmes following 2-week inter-
disciplinary rehabilitation. Primary outcomes were 
ADL motor and ADL process ability, measured with 
the Assessment of Motor and Process Skills (AMPS) 
at 4-week follow-up. Data were analysed per pro-
tocol.
Results: Participants (ADAPT, n = 21; ACTIVE, n = 27) 
did not differ from withdrawers (n = 37). Improve-
ments in ADL ability in the ADAPT (ADL motor mean 
change = 0.43 logits (95% confidence interval (95% 
CI) = 0.31–0.56); ADL process mean change = 0.34 
logits (95% CI = 0.17–0.52)) and ACTIVE (ADL 
motor mean change = 0.33 logits (95% CI = 0.22–
0.43); ADL process mean change = 0.25 logits (95% 
CI = 0.12–0.38)) groups were statistically signifi-
cant, with no differences between groups. Respon-
der analyses revealed that 63% of all participants 
obtained clinically relevant improvements in ADL 
motor ability and 48% in ADL process ability.
Conclusion: Although limited by a large drop-out, 
this exploratory study showed that both adaptation 
and physical activity programmes following interdis-
ciplinary rehabilitation improved ADL ability in the 
majority of participants. ADL ability outcomes were 
independent of group allocation (ADAPT vs ACTIVE), 
suggesting efficacy of both programmes.
Key words: occupational therapy; physiotherapy; Assess-
ment of Motor and Process Skills; ADL; intervention; reha-
bilitation.
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Improved functioning is a main goal of rehabilita-tion (1, 2). Essential to functioning is the ability to 
perform activities of daily living (ADL), such as self-
care and household tasks (1, 2). ADL ability in women 
with fibromyalgia encountered in tertiary care has been 
shown to be significantly reduced, and the extent of 
ADL task performance problems often cause these in-
dividuals to need assistance for safe community living 
(3). Multidisciplinary and interdisciplinary rehabilita-
tion is recommended (4, 5), but despite clinically rele-
vant improvements in ADL ability after rehabilitation, 
women with fibromyalgia still show considerable ADL 
disability and large inter-individual patient variability 
in functional gains (6). It has therefore been suggested 
that clinical effectiveness may be promoted if inter-
vention programmes are more individually tailored 
and specifically designed to improve ADL ability (6). 
Exercise (e.g. aerobic, strength and flexibility train-
ing) and physical activity (e.g. recreational physical 
activity, sports and brisk walking) are recommended 
in the management of fibromyalgia to improve functio-
ning, including ADL ability (7, 8). Studies, however, 
report problems related to adherence, adverse events 
and high drop-out rates (7, 8) and severely impacted 
persons seem to gain less effect (9). Thus, while some 
benefit from exercise/physical activity, others may 
need other types of intervention to improve ADL 
ability.
Interventions focusing on adaptation emphasize 
helping persons to adapt to situations and change the 
environment, rather than focusing on restoration of 
body functions and structures (10, 11). Adaptation 
includes the use of strategies to compensate for per-
formance problems, such as changing routines, using 
assistive devices, and modifying tasks and physical/
social environments (12). Adaptation is not associated 
with adverse events (5) and has been shown to improve 
ADL ability in populations with various chronic health 
conditions (13, 14). Adaptation is also recommended 
as part of rehabilitation for people with fibromyalgia 
(5, 15), although evidence supporting its efficacy is 
lacking. 
Thus, the aim of this exploratory study was to in-
vestigate changes in ADL ability and to compare ADL 
ability outcomes of adaptation and physical activity 
programmes following a 2-week interdisciplinary re-
habilitation programme in women with fibromyalgia. 
As exercise/physical activity seems to be effective in 
some individuals with fibromyalgia (7–9), others might 
benefit from adaptation. It was therefore assumed 
that both programmes would enhance ADL ability 
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outcomes and that no programme would be superior 
to the other. 
METHODS
Study design and participants 
This exploratory, quasi-randomized study was conducted from 
January 2012 to February 2013. The study constituted the second 
phase of the IMPROvE study (Interdisciplinary Rehabilitation 
of Patients with Chronic Widespread Pain: Primary Endpoint 
of the Randomised, Non-Blinded, Parallel-Group IMPROvE 
Trial) (6), approved by the local ethics committee of the Capital 
Region of Denmark (H-2-2010-139), carried out in accordance 
with principles of the Declaration of Helsinki and registered 
with www.clinicaltrials.gov, number NCT01352052. While 
phase I/IMPROvE (6) investiged outcomes of a 2-week inter-
disciplinary rehabilitation programme, this phase II/IMPROvE 
explored outcomes of the same 2-week interdisciplinary rehabi-
litation programme followed by additional 16-week adaptation 
or physical activity programmes (Fig. 1). Participants in the 
IMPROvE study were recruited from the outpatient clinic at 
the Department of Rheumatology, Bispebjerg-Frederiksberg 
Hospital, Denmark; all women, > 18 years of age and fulfilled 
the 1990 American College of Rheumatology (ACR) classifica-
tion criteria for fibromyalgia (16). 
Quasi-randomization and blinding
Participants acting as waiting list control group in phase I/
IMPROvE were consecutively enrolled in the interdisciplinary 
rehabilitation programme in groups of 8. Groups (n = 12) were 
then quasi-randomized by coin-flip by a biostatistician who was 
not involved in the study. Odd-numbered groups (i.e. 1, 3, 5, 7, 
9, 11) were allocated to the adaptation programme (ADAPT) 
and even-numbered groups (i.e. 2, 4, 6, 8, 10, 12) to the phy-
sical activity programme (ACTIVE). Neither staff involved in 
the interdisciplinary rehabilitation programme nor participants 
were informed about group allocation until the last day of the 
interdisciplinary rehabilitation programme, where the therapists 
conducting the ADAPT and ACTIVE programmes revealed the 
allocation. Assessments were performed by blinded assessors 
not informed about the participants’ allocation and not involved 
in the ADAPT and ACTIVE programmes. Questionnaires were 
completed using touch screens, which have been shown to give 
comparable results to answers given on paper (17).
Interdisciplinary rehabilitation programme
The interdisciplinary rehabilitation was a 2-week outpatient, 
group-based programme conducted by a rheumatologist, psy-
chologist, nurse, and occupational and physical therapists. The 
programme had a daily time schedule between 3 and 5 h and 
included a team conference aiming at monitoring individuals’ 
progression towards overall rehabilitation goals, i.e. increasing 
functional ability and coping with pain (6). 
ADAPT and ACTIVE programmes 
The ADAPT and ACTIVE programmes were developed to in-
vestigate whether adaptation and physical activity programmes 
provided as an add-on would enhance ADL ability outcomes in 
women with fibromyalgia. Both programmes lasted 16 weeks, 
were group-based and inspired by an existing programme (18) 
supporting education, reflection, brainstorms, group discussions 
and peer exchange, as a means to promote changes in everyday 
life. Sessions typically began with a short lecture or a discus-
sion initiated by the therapist posing a question. Over time 
the participants were to assume the role of experts and share 
knowledge from their own experiences. The programmes were 
primarily education-based and, to a lesser extent, encompassed 
practical exercises. Participants were encouraged to implement 
adaptation strategies or increase the level of physical activity 
at home in-between sessions. 
ADAPT programme. The ADAPT programme (Appendix I) 
was developed and led by an occupational therapist, included 
16 2-h sessions and aimed at improving ADL ability by means 
of adaptation (10–12). This approach was based on the assump-
tion that adaptation strategies could be used to compensate for 
task performance problems and thus improve ADL ability. The 
compensatory and educational models (12) were used 
as primary means to teach the participants how to 
adapt more successfully, i.e. how to solve ADL task 
performance problems by implementing adaptation 
strategies, such as assistive devices, modifications of 
ADL tasks, and physical and/or social environments. 
The sessions took place in a clinical ADL unit, i.e. a 
2-room flat used to observe and practice ADL task 
performance in a simulated, but naturalistic, home 
environment. 
ACTIVE programme. The ACTIVE programme (Ap-
pendix II) was developed and led by a physiotherapist, 
included 10 2-h sessions and aimed at improving 
ADL ability by means of graded physical activity 
(19, 20). This approach was based on the assump-
tion that increased physical activity improves body 
functions and structures and allows ADL tasks to be 
performed at a lower percentage of maximum capacity 
(7). Education was the primary means to implement 
strategies to increase physical activity in everyday 
life. The programme was conducted in a clinical unit 
fitted for group discussions and performance of light 
exercises (e.g. resistance-band exercises).Fig. 1. IMPROvE study design for phase I and phase II.
Inclusion
Total group(n=192)
2-weeks interdisciplinary
rehabilitation program
Group A (n=96)
6-months waiting list 
control
Group B (n=96)
pre-intervention assessment
pre-intervention assessment (A1)
2-weeks interdisciplinary
rehabilitation program 
Group (n=96)
16-weeks ADAPT program 
Group (n=48)
16-weeks ACTIVE program 
Group (n=48)
4-weeks post-intervention assessment (A3)
Phase I
Phase II
pre-post intervention assessment (A2)
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Procedures 
The study included 3 assessments points. Baseline assessment 
1 (A1) was performed 3 weeks prior to the interdisciplinary re-
habilitation programme. There was approximately 1 month bet-
ween the end of the interdisciplinary rehabilitation programme 
and the beginning of the additional programmes. Assessment 2 
(A2) was performed 3 weeks after the rehabilitation programme, 
and served as a baseline prior to entry to the additional program-
mes. For logistical reasons, assessment 3 (A3) was performed 4 
weeks after the additional ADAPT/ACTIVE programmes (Fig. 
1). While the primary endpoint was change during the interdis-
ciplinary rehabilitation programme and additional ADAPT or 
ACTIVE programmes (A1–A3), the secondary endpoint was 
change during the additional programmes (A2–A3). 
Primary outcome
Change in observed ADL ability was the primary outcome 
measured with the Assessment of Motor and Process Skills 
(AMPS) (21). 
Assessment of Motor and Process Skills (AMPS). The AMPS 
evaluates 2 aspects of ADL ability; ADL motor ability (amount 
of effort, fatigue and/or clumsiness) and ADL process ability 
(degree of disorganization, inappropriate use of time, space 
or objects and adapting actions) (21). The quality of 16 ADL 
motor skills (move self and objects) and 20 ADL process skills 
(organize and adapt actions) is scored on a 4-point ordinal 
scale in terms of ease, efficiency, safety, and independence. 
Raw scores are analysed using a many-faceted Rasch-based 
computer-scoring software program, which converts the raw 
ordinal scores into 2 overall linear measures of ADL motor 
and ADL process ability, expressed in logits (i.e. logistically 
transformed probability units) adjusted for rater severity as 
well as ADL task and skill item difficulty (21). Both the AMPS 
ADL motor ability measure and the AMPS ADL process ability 
measure served as primary outcomes in this study. ADL ability 
measures below the 1.50 logit independence cut-off on the ADL 
motor scale and below the 1.00 logit independence cut-off on 
the ADL process scale indicate a likely need for assistance (21). 
Measures below the lower independence cut-offs of 1.00 and 
0.70 logits for ADL motor and ADL process ability, respectively, 
mark a need for moderate/maximal assistance (22). The AMPS 
has demonstrated sound psychometric properties when applied 
to women with fibromyalgia, including sensitivity to change 
post-intervention (23). According to the AMPS manual (21) a 
difference of ≥ 0.30 logits on the ADL motor and/or ADL process 
scales defines a clinically relevant difference in ADL ability.
Secondary outcomes
Secondary outcomes included self-reported ADL ability eva-
luated with the ADL-Questionnaire (ADL-Q) (24) and the 
physical functioning subscale of the MOS 36-item Short Form 
(25) (SF-36 PF). Disease severity was evaluated with the total 
score of the Fibromyalgia Impact Questionnaire (FIQ) (26) and 
pain with the FIQ pain subscale. Health-related quality of life 
was evaluated with the SF-36 Physical Composite Score (PCS) 
and Mental Composite Score (MCS) (25).
ADL-Questionnaire (ADL-Q). ADL-Q is a standardized instru-
ment developed to measure a person’s perceived quality of ADL 
task performance in 12 domains related to 47 ADL tasks. The 
person marks the quality of the ADL task performance using 7 
response categories reflecting efficiency, effort/fatigue, safety, 
and independence. ADL-Q requires Rasch-measurement met-
hods in order to convert the raw ordinal data into linear measures 
of ADL ability (24, 27). The ADL-Q has demonstrated sensiti-
vity to change when applied in women with fibromyalgia (24). 
Clinically relevant differences were determined based on the 
criterion of 0.5 standard deviation (SD) (28) for a comparable 
study sample (29), i.e. ≥ 1.00 logits. 
MOS 36-Item Short Form (SF-36). The SF-36 is a generic instru-
ment constructed to evaluate physical and mental health-related 
quality of life expressed in 2 composite scores, i.e. SF-36 PCS 
and SF-36 MCS. The ordinal scale scores are transformed into 
linear scales, ranging from 0 to 100, and standardized to reflect 
a general population (US) mean of 50 (SD 10). Measures of 0 
= worst possible health status, and 100 = best health status. The 
SF-36 PF subscale evaluates the extent of perceived limitations 
of task performance due to health-related problems (i.e. perform 
vigorous and moderate activities, lift or carry groceries, climb 1 
or several flights of stairs, make beds, walk 1 block or more than 
1 mile, and bathe or dress). Response categories are scored on 
a 3-point Likert scale (i.e. 1 = limited to 3 = not limited at all). 
Raw scores are summed into 1 overall score for functioning, 
ranging from 0 to 100 points, in which 0 = severely limited and 
100 = the person performs all types of tasks (25). Based on the 
criterion of 0.5 SD (28) in a comparable study sample (30), clini-
cally relevant differences were determined as: SF-PF ≥ 10.00 
points, SF-36 PCS ≥ 3.34 points and SF-36 MCS > 5.98 points. 
Fibromyalgia Impact Questionnaire (FIQ). FIQ is a disease-
specific questionnaire, composed of 10 subscales, designed to 
evaluate disease severity (FIQ total). The average person with 
fibromyalgia is expected to obtain a FIQ total score of approx-
imately 50 points, whereas more severely impacted persons 
score > 70 out of 100 (31). The fifth item in the FIQ is a 100-mm 
visual analogue scale (VAS) used to evaluate pain intensity; 0 
= no pain to 10 = very severe pain (26). Based on the criterion 
of 0.5 SD (28) in a comparable study sample (30), clinically 
relevant differences were determined as: FIQ total ≥ 9.27 points 
and FIQ pain > 0.98 mm.
Statistical and responder analyses
Sample size was based on the sample size calculation from 
phase I/IMPROvE (6). With AMPS as primary outcome, a 
2-sample pooled t-test of a normal mean difference with a 
2-sided significance level of 0.05, assuming a common SD 
of 0.4, a sample size of 86 per group was required to obtain a 
power of at least 0.9 to detect a group mean difference of 0.2 
(6). Because participants would be enrolled in groups of 8 it was 
decided to include 96 participants in each arm, thus including 
a total of 192 participants in phase I/IMPROvE (Fig. 1). This 
sample size calculation allowed for an expected drop-out rate 
of 20% in phase II/IMPROvE. Efficacy was analysed on a per 
protocol basis, only including participants with an attendance 
of at least 25% in the additional programmes. Participants 
who withdrew or attended less than 25% were not reassessed 
4-weeks post-intervention. Consequently, no intention-to-treat 
analyses were performed. Distribution of data was tested for 
normality. Primary outcomes, i.e. AMPS ADL ability measu-
res, were investigated using analyses of variance (ANOVA) 
with time (A1, A2, A3) by programme (ADAPT/ACTIVE) 
as repeated measure, followed by post hoc paired-samples 
and independent-samples t-tests, and reported as means and 
95% confidence intervals (95% CI) at the primary (A1–A3) 
and secondary endpoints (A2–A3). Secondary outcomes were 
analysed at the primary endpoint. Changes in the linear ADL-Q 
J Rehabil Med 49, 2017
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measures were analysed and compared using paired-samples and 
independent-samples t-tests, while changes in the ordinal SF-36 
and FIQ scores were analysed and compared using Wilcoxon 
signed-rank test and Mann–Whitney U test and reported in 
medians and quartiles (Q).
Responders were defined as participants achieving a clinically 
relevant improvement in ADL ability measures on instruments 
specifically designed to measure ADL ability, i.e. the AMPS 
(≥ 0.30 logits) and ADL-Q (≥ 1.00 logits). The proportions 
(number and percentages) of responders were calculated and 
compared by Pearson’s χ2 tests and mean 
changes in observed and self-reported 
ADL ability for responders were analysed 
and compared using paired-samples and 
independent-samples t-tests and reported 
in means and 95% CI. SPSS software was 
used in all analyses (32).
RESULTS
Recruitment and participants’ 
characteristics
Overall, 85 participants were en-
rolled in the interdisciplinary re-
habilitation programme and were 
quasi-randomized to the ADAPT 
(n = 43) or ACTIVE (n = 42) pro-
grammes. Fig. 2 illustrates the flow 
of participants through the study, 
including time points and reasons 
for the large dropout (n = 37). Base-
line characteristics for participants 
completing the ADAPT or ACTIVE 
programmes and participants who 
withdrew are presented in Table I. 
In all 3 groups, the pain duration 
averaged 10 years and participants 
reported high levels of pain and fati-
gue. ADL ability measures indicated 
considerable disability, 72% were 
unemployed, and 44% had a pending social welfare 
application. No significant differences in baseline 
characteristics between the 3 groups were identified.
Primary outcomes at primary and secondary endpoints
Changes over the 3 assessment points (A1–A3) in 
primary outcomes, i.e. AMPS ADL motor and process 
Fig. 2. CONSORT flow diagram showing participants’ flow through the study. A1, A2, A3; 
assessments 1, 2, 3.
Baseline assessments (A1) (n=85) 
Assessed at A3 and included in the per 
protocol analysis (n=21) 
!
Lost to four-week follow-up (n=0) 
Allocated to ADAPT program (n=43) 
Total withdrawers (n=22) 
Withdrew from the interdisciplinary    
   rehabilitation program and consequently    
   not assessed at A2 (n=3) 
 Withdrew prior to ADAPT (n=15) due to 
- Could not incorporate the program into 
life situation (energy/work/family) (n=7) 
- Transportation (n=5) 
- Family issues (n=1) 
- Could not be contacted (n=1) 
- Not motivated for the program (n=1) 
 Attended ADAPT <25% (n=4)  
Lost to four-week follow-up (n=0) 
 
Allocated to ACTIVE program (n=42) 
Total withdrawers (n=15) 
Withdrew from the interdisciplinary    
   rehabilitation program and consequently  
   not assessed at A2 (n=3) 
 Withdrew prior to ACTIVE (n=9) due to 
- Could not be contacted (n=5) 
- Transportation (n=3) 
- Health related issues (n=1) 
 Attended ACTIVE <25% (n=3)  
Assessed at A3 and included in the per 
protocol analysis (n=27)
Allocation 
Analysis 
Follow-Up 
Quasi-randomization (n=85)   
Enrollment 
Enrolled into the interdisciplinary 
rehabilitation program (n=85) 
Table I. Baseline characteristics for the total sample and when grouped into ADAPT participants, ACTIVE participants and withdrawers
Variables (A1) Total (n = 85) ADAPT (n = 21) ACTIVE (n = 27) Withdrawers (n = 37)
Age, years, mean (95% CI) 45.3 (42.8–47.7) 43.4 (38.8–49.0) 44.7 (40.2–49.1) 47.0 (43.4–50.5)
Duration of pain, years, mean (range) 10.0 (5–15) 10.0 (5–15) 9.5 (5–16) 9.5 (4–15)
Tender point count, medians (IQR) 18 (18–18) 18 (18–18) 18 (18–18) 18 (18–18)
Unemployed due to the pain condition, n (%) 61 (72) 18 (86) 19 (70) 24 (65)
Pending social welfare application, n (%) 37 (44) 12 (57) 9 (33) 16 (43)
AMPS ADL motor, mean (95% CI) 1.15 (1.05–1.26) 1.13 (0.97–1.29) 1.10 (0.91–1.28) 1.21 (1.01–1.40)
AMPS ADL process, mean (95% CI) 0.90 (0.84–0.96) 0.83 (0.72–0.95) 0.90 (0.80–1.00) 0.93 (0.81–1.05)
ADL-Q, mean (95% CI) 2.18 (1.78–2.63) 2.26 (1.44–3.22) 2.14 (1.47–2.88) 2.17 (1.43–2.96)
SF-36 PF, median (IQR) 40.0 (25–55) 35.0 (23–40) 45.0 (30–60) 45.0 (21–55)
SF-36 PCS, median (IQR) 26.9 (22–32) 24.4 (20–28) 28.0 (23–32) 27.8 (22–34)
SF-36 MCS, median (IQR) 38.8 (31–49) 38.8 (30–50) 41.3 (36–51) 37.8 (28–45)
FIQ total, median (IQR) 64.1 (55–74) 64.1 (55–74) 59.1 (53–70) 63.9 (58–77)
FIQ pain, median (IQR) 7.7 (6–9) 7.8 (6–9) 7.6 (6–8) 7.7 (6–9)
FIQ fatigue, median (IQR) 9.1 (8–10) 9.2 (8–10) 8.6 (7–10) 9.1 (8–10)
ADAPT: adaptation programme; ACTIVE: physical activity programme; 95% CI: confidence interval; IQR: interquartile range; AMPS: Assessment of Motor and 
Process Skills; ADL: activities of daily living; ADL-Q: ADL-Questionnaire; SF-36: MOS 36-item Short Form; SF-36-PF: Physical Functioning; SF-36 MCS: Mental 
Composite Score; SF-36 PCS: Physical Composite Score; FIQ: Fibromyalgia Impact Questionnaire; A1: Assessment 1.
www.medicaljournals.se/jrm
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ability measures are illustrated in Fig. 3a–b. Impro-
vements in ADL motor ability in the ADAPT (mean 
change = 0.43; 95% CI = 0.31 to 0.56) and ACTIVE 
(mean change = 0.34; 95% CI = 0.17 to 0.52) groups 
from baseline (A1) to 4-week follow-up (A3) were sta-
tistically significant and clinically relevant, but without 
significant differences across groups (95% CI = –0.13 
to 0.32) (Table II). In addition, the ADL process ability 
improved statistically significant in the ADAPT (mean 
change = 0.33; 95% CI = 0.22 to 0.43) and ACTIVE 
(mean change = 0.25; 95% CI = 0.12 to 0.38) groups 
at the primary endpoint, but only the improvement in 
the ADAPT group was clinically relevant and there 
were no significant group differences (95% CI = –0.11 
to 0.25) (Table II). 
At the secondary endpoint (A2–A3), i.e. prior to the 
additional programmes (A2) to 4-week follow-up (A3), 
the ADL motor ability improved statistically significant 
in the ADAPT group (mean change = 0.25: 95% CI 
= 0.13 to 0.37), but not in the ACTIVE group (mean 
change = 0.04; 95% CI = –0.07 to 0.15). The difference 
between groups was statistically significant (95% CI 
= 0.03 to 0.39) (Table II). No significant changes in 
ADL process ability in either of the groups (ADAPT: 
mean change = 0.07; 95% CI = 0.00 to 0.15; ACTIVE: 
mean change = 0.07; 95% CI = –0.01 to 0.15) were 
observed at this assessment point (Table II). 
Secondary outcomes at primary endpoint
While the ADAPT group reported no significant 
change in ADL ability evaluated with ADL-Q (mean 
change = –0.21; 95% CI = –1.40 to 0.80), the ACTIVE 
group reported statistically significant lower levels of 
ADL ability (mean change = –0.63; 95% CI = –1.13 
to –0.16). This observed decline, however, was not 
clinically relevant and differences between groups in 
ADL-Q ADL ability was not statistically significant 
(p = 0.47) (Table II). None of the other self-reported 
secondary outcomes showed any significant change 
over time or differences at group level (Table II). 
Fig. 3. (a) Mean changes in AMPS ADL motor ability over time. (b) 
Mean changes in AMPS ADL process ability over time. (A1, A2, A3) by 
programme (ADAPT/ACTIVE). ADAPT: adaptation programme; ACTIVE: 
physical activity programme; AMPS: Assessment of Motor and Process 
Skills; ADL: activities of daily living; A1, A2, A3: Assessment 1, 2, 3.
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Table II. Changes in primary outcomes at primary and secondary endpoints and secondary outcomes at primary endpoint
Variables ADAPT (n = 21) ACTIVE (n = 27) Group difference (95% CI)
Primary outcomes at primary endpoint (A1–A3)
AMPS ADL motor ability, mean (95% CI) 0.43 (0.31 to 0.56) 0.34 (0.17 to 0.52) 0.09 (–0.13 to 0.32)
AMPS ADL process ability, mean (95% CI) 0.33 (0.22 to 0.43) 0.25 (0.12 to 0.38) 0.07 (–0.11 to 0.25)
Secondary outcomes at primary endpoint (A1–A3) Group differences (p-value)
ADL-Q, mean (95% CI) –0.21 (–1.40 to 0.80) –0.63 (–1.13 to –0.16) (0.47)
SF-36 PF, median (IQR) 0.00 (–7.50 to 7.50) –5.00 (–12.50 to 10.00) (0.53)
SF-36 MCS, median (IQR) 3.84 (–3.24 to 10.87) 2.89 (–3.65 to 7.11) (0.61)
SF-36 PCS, median (IQR) –0.60 (–3.53 to 2.54) –1.82 (–7.18 to 3.64) (0.52)
FIQ total, median (IQR) 0.05 (–8.94 to 11.92) –1.06 (–8.00 to 9.32) (0.66)
FIQ pain, median (IQR) 0.20 (–0.80 to 0.80) 0.75 (–0.90 to 1.43) (0.38)
Primary outcome at secondary endpoint (A2–A3) Group difference (95% CI)
AMPS ADL motor ability, mean (95% CI) 0.25 (0.13 to 0.37) 0.04 (–0.07 to 0.15) 0.21 (0.03 to 0.39)
AMPS ADL process ability, mean (95% CI) 0.07 (0.00 to 0.15) 0.07 (–0.01 to 0.15) 0.00 (–0.11 to 0.12)
ADAPT: adaptation programme; ACTIVE: physical activity programme; 95% CI: 95% confidence interval; IQR: interquartile ranges; AMPS: Assessment of Motor 
and Process Skills; ADL: activities of daily living; ADL-Q: ADL-Questionnaire; SF-36: MOS 36-item Short Form; SF-36-PF: Physical Functioning; SF-36 MCS: Mental 
Composite Score; SF-36 PCS: Physical Composite Score; FIQ: Fibromyalgia Impact Questionnaire; A1, A2, A3: Assessment 1, 2, 3. 
Statistically significant differences are marked in italic and clinically relevant improvements are marked in bold.
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Responder analyses
Responder analyses revealed that 63% (30/48) of the 
total sample obtained clinically relevant improvements 
in ADL motor ability (mean change = 0.60; 95% CI 
= 0.51 to 0.70) and 48% (23/48) in ADL process ability 
(mean change = 0.53; 95% CI = 0.47 to 0.61) at the 
primary endpoint. Sixty-seven percent (14/21) in the 
ADAPT group showed clinically relevant improve-
ments in ADL motor ability (mean change = 0.58; 95% 
CI = 0.48 to 0.71) and 52% (11/21) in ADL process 
ability (mean change = 0.52; 95% CI = 0.43 to 0.59). 
In comparison, 59% (16/27) in the ACTIVE group sho-
wed clinically relevant improvements in ADL motor 
ability (mean change = 0.62; 95% CI = 0.47 to 0.77) 
and 44% (12/27) in ADL process ability (mean change 
= 0.55; 95% CI = 0.45 to 0.67) at the primary endpoint. 
Measures at the secondary endpoint showed that 71% 
(10/14) of the ADAPT responders and 50% (8/16) of 
the ACTIVE responders gained their ADL motor abi-
lity improvements during the additional programmes. 
Correspondingly, 18% (2/11) and 25% (3/12) of the 
responders gained their ADL process ability improve-
ments during the ADAPT and ACTIVE programmes, 
respectively. Neither the proportion of responders 
nor the mean improvements in ADL ability differed 
statistically significant between groups at primary or 
secondary endpoints (Table III). 
Subgroup analysis showed that in ADAPT/ACTIVE 
responders the mean ADL motor ability measure was 
0.91 (95% CI =0.78 to 1.04) logits and the mean ADL 
process ability measure 0.68 (95% CI = 0.61 to 0.75) 
logits at baseline (A1). These ability measures were 
clinically and statistically significantly lower (ADL 
motor mean difference = 0.58; 95% CI = 0.43 to 0.74: 
ADL process mean difference = 0.47; 95% CI = 0.36 
to 0.59) than baseline measures for the non-responders 
(ADL motor ability = 1.45; 95% CI = 1.28 to 1.61: ADL 
process ability = 1.05; 95% CI = 0.96 to 1.13). 
A total of 10% (5/48) reported clinically relevant 
improvements (mean change = 2.50; 95% CI = 1.45 
to 4.33) in ADL ability at the primary endpoint on 
the ADL-Q, while 90% (43/48) reported no clinically 
relevant change (mean change = –0.80; 95% CI = –1.34 
to –0.38). 
DISCUSSION
To our knowledge, this is the first study to explore 
changes in ADL ability and compare the ADL ability 
outcomes of individually tailored add-on adaptation 
or graded physical activity programmes following an 
interdisciplinary rehabilitation programme in women 
with fibromyalgia. The results of this exploratory study 
indicated that participants achieved statistically signi-
ficant improvements in ADL motor and ADL process 
ability at 4-week post-intervention independent of 
group allocation to the ADAPT vs the ACTIVE pro-
gramme. Although responder analyses demonstrated 
inter-individual patient variability, clinically relevant 
improvements in ADL motor and ADL process ability 
were observed in 63% and 48% of the overall study 
sample, respectively. No previous studies have shown 
similar functional responder rates among women with 
fibromyalgia. 
In phase I/IMPROvE (6), evaluating the outcomes 
of the interdisciplinary rehabilitation programme, 
36% of the participants obtained clinically relevant 
improvements in ADL motor ability and 18% in ADL 
Table III. Proportion of responder and mean changes in activities of daily living (ADL) ability at primary and secondary endpoints
Variables ADAPT ACTIVE Group differences
Responders on primary outcome at primary endpoint (A1–A3)
AMPS ADL motor ability, n (%) 14 (67) 16 (59) χ2= 0.28; df= 1; p = 0.60
Change, mean (95% CI) 0.58 (0.48–0.71) 0.62 (0.47–0.77) –0.03 (–0.24 to 1.18)
Ability at A1, mean (SD) 0.99 (0.80–1.19) 0.85 (0.67–1.04) 0.14 (–0.14 to 0.43)
AMPS ADL process ability, n (%) 11 (52) 12 (44) χ2 = 0.30; df= 1; p = 0.59
Change, mean (95% CI) 0.52 (0.43–0.59) 0.55 (0.45–0.67) –0.03 (–0.19 to 0.12)
Ability at A1, mean (95% CI) 0.64 (0.58–0.72) 0.71 (0.59–0.82) –0.07 (–0.22 to 0.09)
ADL-Q ADL ability, n (%) 2 (10) 3 (11) χ2= 0.02; df= 1; p = 0.89
Change, mean (95% CI) 4.00 (2.09–5.93) 1.51 (1.14–1.81) 2.49 (–2.16 to 7.14)
Ability at A1, mean (95% CI) 1.53 (1.21–1.85) 1.53 (0.51–3.25) 0.01 (–3.64 to 3.65)
Responders on primary outcome at secondary endpoint (A2–A3)
AMPS ADL motor ability, n (%) 10 (48) 8 (30) χ2= 1.63; df= 1; p = 0.20
Change, mean (95% CI) 0.51 (0.43–0.59) 0.46 (0.38–0.53) 0.06 (–0.09 to 0.19)
Ability at A2, mean (95% CI) 1.11 (0.96–1.23) 1.28 (1.10–1.41) 0.17 (–0.41 to 0.07)
AMPS ADL process ability, n (%) 2 (10) 3 (11) χ2= 0.03; df= 1; p = 0.86
Change, mean (95% CI) 0.37 (0.35–0.39) 0.46 (0.39–0.51) –0.09 (–0.25 to 0.07)
Ability at A2, mean (95% CI) 0.86 (0.74–0.97) 0.77 (0.66–0.89) 0.08 (–0.30 to 0.47)
ADAPT: adaptation programme; ACTIVE: physical activity programme; 95% CI: confidence interval; IQR: interquartile ranges; AMPS: Assessment of Motor and 
Process Skills; ADL-Q: ADL-Questionnaire; SF-36: MOS 36-item Short Form; SF-36-PF: Physical Functioning; SF-36 MCS: Mental Composite Score; SF-36 PCS: 
Physical Composite Score; FIQ: Fibromyalgia Impact Questionnaire; A1, A2, A3: Assessment 1, 2, 3. Responders on the AMPS had changed > 0.3 logits in ADL 
motor and/or ADL process ability. Responders on the ADL-Q had changed > 1.00 logits.
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process ability, respectively. Thus, adding additional 
programme components to the rehabilitation pro-
gramme, which were specifically developed to improve 
ADL ability, seems to have improved functional gains 
considerably, even in this sample of women with 
fibromyalgia presenting with substantial disability 
established over many years. 
Assessed with the AMPS, the observed performance 
difficulties in our study sample were dominated by 
decreased ADL motor ability and it was within this 
domain that most participants achieved a clinically 
meaningful improvement. The study revealed no sig-
nificant differences between the ADAPT and ACTIVE 
groups in ADL motor ability outcome at the primary 
endpoint, suggesting efficiency of both programmes. 
However, the observed larger mean change in ADL 
motor ability and a 95% CI indicating a clinically re-
levant improvement in the majority of participants in 
the ADAPT group, could indicate that this programme 
was superior to the ACTIVE programme. Overall, the 
participants attending the ADAPT programme obtai-
ned a mean change of 0.43 (95% CI = 0.31 to 0.56) 
logits in ADL motor ability vs 0.34 (95% CI = 0.17 to 
0.52) logits in the ACTIVE programme. Although not 
significant, the notion of a better ADL motor ability 
outcome in the ADAPT programme was further sup-
ported by a higher proportion of ADL motor responders 
in this group, 48% vs 30% in the ACTIVE group. This 
could indicate that participants in the ACTIVE group 
had more differential treatment effects compared with 
participants in the ADAPT group, possibly reflecting 
problems with adherence. Adherence constitutes a 
known problem in fibromyalgia, as physical activity 
may be experienced to increase symptoms (8). The 
seemingly less differential treatment response and 
higher responder rate in the ADAPT group may support 
a broader relevance of applying adaptation strategies 
to improve ADL ability in women with moderate to 
severe fibromyalgia. Adaptation may be an easier and 
better tolerated approach and may therefore promote 
adherence. This hypothesis, however, needs testing in 
future larger studies.
Post hoc subgroup analysis revealed significant ba-
seline (A1) differences in the AMPS ADL profiles of 
responders and non-responders. At baseline, the non-
responders presented with overall higher levels of ADL 
ability, i.e. they used less effort, were more efficient, 
safe and independent during ADL task performance 
compared with responders. Responders presented with 
ADL ability measures below the lower independence 
cut-offs at baseline, indicating increased effort, fati-
gue, inappropriate use of time, space or objects and 
decreased ability to adapt actions efficiently during ADL 
task performance. The observed extent of performance 
problems probably caused these participants to have 
a need for moderate/maximal assistance in everyday 
life prior to entering the intervention (21). At 4-week 
post-intervention the obtained AMPS ADL ability 
measures in the responders indicated that ADL tasks 
were performed with significantly less effort, increased 
efficiency, less safety risk and less need of assistance. 
These findings are in accordance with existing guideli-
nes, recommending interdisciplinary rehabilitation for 
more severely impacted persons (4, 5). The results of this 
study, however, seem to support the relevance of offering 
additional targeted interventions, as the majority of the 
participants gained their improvements in ADL motor 
ability during the additional programmes (A2–A3). 
Despite the observed clinically relevant improve-
ments in AMPS ADL ability measures among a rather 
large proportion of the participants, only 10% reported 
clinically relevant improvements in ADL ability using 
the ADL-Q. Several studies (24, 33, 34) support that 
self-report and observation provides distinct informa-
tion about ADL ability and cannot substitute for each 
other. Individuals’ perception of functioning seems to 
be influenced by factors such as disease severity, pain 
and health-related quality of life, and may therefore not 
reflect actual performance (34). As none of these fac-
tors changed during the intervention the participants’ 
reporting may still be influenced. The lack of changes 
in disease severity, pain and health-related quality of 
life suggests that assessments at the body level and 
global assessments, cannot substitute for observation-
based evaluation of ADL ability (34). 
The study had several limitations. Due to the study 
design, with no control group, it was only possible to 
evaluate the ADL ability outcome of the combined 
intervention and not of the individual ADAPT and 
ACTIVE programmes. Still, it seems that the additional 
programmes significantly enhanced the proportion of 
responders. The study included only moderately/se-
verely impacted women with fibromyalgia and findings 
may therefore not be generalized to the overall referral 
population. A large proportion of the sample withdrew 
prior to the ADAPT/ACTIVE programmes; however, 
the reasons for dropping out were not adverse events, 
as reported previously (7, 8). The resulting smaller 
sample size, the lack of intention-to-treat analysis and 
per protocol analysis may have increased the risk of 
overestimating outcomes, whereas the use of blinded 
assessors is considered to reduce reporting bias (35). 
The small sample size may also have underpowered the 
study to identify changes in secondary outcomes and 
differences between groups, and future larger studies 
are therefore warranted. 
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In conclusion, although limited by a large dropout 
rate, the study showed that both adaptation and phy-
sical activity programmes following interdiscipli-
nary rehabilitation improved observed ADL ability, 
as indicated by decreased effort, increased efficiency, 
safety and independence. These improvements were 
identified in more than two-thirds of a sample of wo-
men with fibromyalgia presenting with longstanding 
pain and substantial ADL disability at baseline. No 
significant group differences were observed in this 
smaller study sample, indicating efficiency of both 
programmes. Still, the study pointed towards less dif-
ferential treatment response and higher responder rate 
in participants allocated to adaptation. Thus, the results 
of this exploratory study provide initial evidence for 
using adaptation to improve ADL ability in women 
with fibromyalgia, and support existing recommenda-
tions (7, 8) of integrating physical activity programmes 
in the management of fibromyalgia populations. 
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Appendix I. Summary of the ADAPT programme
Objective » To teach and support the participants in developing efficient adaptation strategies to improve ADL ability
Key elements » Identify ADL task performance problems (sessions 1–6) 
» Implement adaptation strategies to compensate for task performance problems (sessions 7–14)  
» Re-evaluate for enhanced and satisfying ADL task performance (sessions 15–16)
Session 1 » Introduction, the beginning of something new 
Presentation, group contract, clarify roles and expectations 
Session 2 » Prioritize roles and meaningful ADL tasks 
How roles are related to ADL tasks; identify important life roles and tasks perceived as crucial to that role 
Session 3 » Analyse ADL task performance 
How to analyse ADL task performance; observe participants perform ADL tasks and identify ineffective ADL skills (e.g. decreased ability 
to move or lift objects and/or decreased ability to organize and adapt performance); discuss which adaptation strategies that may 
compensate for ineffective ADL skills
Session 4 » Analyse ADL task performance (continued from session 3) 
Observe ADL task performance and identify ineffective ADL skills and relevant adaptation strategies
Session 5 » Clarify the causes to ADL task performance problems 
How ADL task performance problems are influenced by the task, the person performing the task and the environment in which the task is 
performed
Session 6 » Set goals and make a plan 
How to define a goal related to ADL task performance; identify factors that may promote or limit the achievements of goals
Session 7 » Use energy conservation principles to decrease effort during ADL task performance 
Introduce energy conservation principles; how does energy conservation principles influence ADL task performance? 
Session 8 » Plan efficient ADL task performance 
Introduction to assistive devices; plan and perform ADL tasks using adaptation strategies
Session 9 » Plan efficient ADL task performance (continued from session 8) 
Plan and perform ADL tasks using adaptation strategies
Session 10 » Apply for assistive devices 
How to apply for assistive devices in home community
Session 11 » Does motivation influence ADL task performance? 
How does motivation influence ADL task performance and how may motivation for performing ADL tasks that are necessary to perform be 
enhanced?
Session 12 » Use ADL tasks to increase physical activity and improve body functions 
Can ADL task performance be categorized as physical activity? Observe ADL task performance and identify ADL skills (e.g. walk and lifts) 
that may improve body functions (e.g. endurance and strengths)
Session 13 » Performance of ADL tasks when having pain 
How may pain influence ADL task performance? Is there a linear correlation between the level of pain and the ability to perform ADL tasks? 
Session 14 » Adapt ADL task performance to fluctuations in ADL ability 
Specify how to perform ADL tasks on a day with less disease severity and how to perform ADL tasks on a day with high disease severity 
and identify tasks that may not need to be performed
Session 15 » Looking back, what did we do, and what did you learn? 
Create a group concept-map to organize and structure learning outcomes; which adaptation strategies have been implemented in ADL task 
performances and how have ADL task performance changed?
Session 16 » Evaluation, celebrating and looking forward 
Discuss future goals and plans 
ADAPT: adaptation programme; ADL: activities of daily living.
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Appendix II. ACTIVE programme
Objective » To teach and support the participants in increasing the level of physical activity in everyday life to improve ADL ability
Key elements » Identify individual training barriers 
» Individual goal-setting 
» Pacing principles 
Session 1 » Introduction, the beginning of something new 
Presentation, group contract, clarify roles and expectations 
Session 2 » Define a goal and reach it 
Define realistic and meaningful goals; pacing principles i.e. how to evaluate present level of physical ability prior to being active in order to 
reduce pain exacerbations and exercise intolerance (20) 
Session 3 » Physical activity in practice 
How to minimize pain exacerbation and exercise intolerance during physical activity; try out different exercises with resistance bands, gym 
balls and exercise on mats as inspiration
Session 4 » Barriers for being physically active 
The need to change habits when wanting to become more physically active; what are the barriers to being physically active and which 
strategies may be used to overcome these barriers?
Session 5 » Pain, physical activity and managing pain 
Central sensitization and the difference between acute and chronic pain; how to manage pain when being physically active 
Session 6 » Mid-term evaluation 
Reflect upon the knowledge gained and the need to adjust personal goals  
Session 7 » Motivation for physical activity in everyday life 
Which kind of physical activity increase level of energy and which kind decrease level of energy? What may increase motivation for being 
physically active in everyday life? 
Session 8 » How has chronic pain influenced your way of being physical active? 
Which kind of physical activity did you enjoy in the past and which kind of physical activity do you perform now? Which kind of physical 
activity would you like to do in the future?
Session 9 » Organize time, energy and physical activity 
How do you match level of energy during the day to the level of physical activity?
Session 10 » Long-term goals – looking back and forward 
Reflect upon knowledge gained, motivation for being physically active and how to progress towards desired goals 
ACTIVE: physical activity programme; ADL: activities of daily living.
www.medicaljournals.se/jrm
